Single-Photon Emission Computed Tomography Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Standalone, Bi-Modal, Tri-Modal, Others ), By Applications (Medical Industry, Mechanical Industry, Others), By Distribution Channel (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers) and Region Forecast 2020-2031  

Single-Photon Emission Computed Tomography Market size was valued at US$ 3,885.1 million in 2024 and is expected to reach US$ 4,707.2 million by 2031, growing at a significant CAGR of 2.8% from 2025-2031. Single-Photon Emission Computed Tomography (SPECT) is a nuclear medicine tomographic imaging technique designed to create three-dimensional images of the body's internal structures and functions using radioactive tracers and gamma-ray detectors. It is a non-invasive diagnostic imaging technique that is essential in the identification, staging, and management of a number of disorders. Single-photon emission computed tomography offers various significant advantages such as high sensitivity, functional imaging capabilities, and the ability to visualize physiological processes in real-time, making it a flexible system for use in the field of imaging technology. The increasing prevalence of cardiovascular problems, neurological conditions, and cancer is one of the major factors driving the market. SPECT imaging provides useful information about the blood flow, metabolism, and function of organs and tissues, aiding in the diagnosis and management of these conditions.

Additionally, the growing geriatric population, who are more prone to these chronic diseases, contributes to the increasing demand for SPECT imaging. According to NCOA data, 80% of people aged 65 and older have at least one chronic disease, and 68% have two or more, which offers potential for the single-photon emission computed tomography industry to develop. On top of that, opportunities for additional market expansion are being created by technological developments in SPECT systems and the growing need for precise and early diagnosis. However, limited access to advanced imaging facilities, high costs associated with equipment and maintenance, and the need for skilled operators are some of the factors that hinder the market growth. Major pharmaceutical industries are continuously developing advanced imaging technologies which are contributing to more accurate diagnoses and better treatment planning. For instance, in June 2022, Siemens Healthineers introduces Symbia Pro. spectra, a single photon emission computed tomography/computed tomography (SPECT/CT) system.

Key Developments

• In November 2021 Siemens Healthineers launched the World’s First Photon-Counting CT Scanner NAEOTOM Alpha that directly detects each X-ray photon and its energy level instead of first converting it into visible light as with conventional CT imaging.
• In August 2020, IMEXHS announced an agreement with Vital Images, Inc., a Canon Group company to authorize Vital Images’ advanced visualisation Vitrea® software